Abstract Number: 0772 • ACR Convergence 2022
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
Background/Purpose: From January 2021 around 60% of the total population has received at least one dose of any COVID-19 vaccine. A minority of vaccinated individuals…Abstract Number: 0793 • ACR Convergence 2022
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
Background/Purpose: Up to 70% of the 236 million people who have been diagnosed with SARS-CoV-2 develop post-COVID symptoms. (1) This has been defined by the…Abstract Number: 0950 • ACR Convergence 2022
Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
Background/Purpose: To describe obstetric outcomes based on COVID-19 vaccination status in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.Methods: We extracted…Abstract Number: 1330 • ACR Convergence 2022
Impact of COVID-19 Severity on Physical Function, Mobility, Falls and Fractures Among Older Patients After Hospitalization: A Longitudinal Study
Background/Purpose: No longitudinal studies have examined the impact of COVID-19 or COVID-19 severity on physical function and disability outcomes among older adults. Multiple factors, including…Abstract Number: 1766 • ACR Convergence 2022
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…Abstract Number: 1939 • ACR Convergence 2022
Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases
Background/Purpose: Long-term data on the safety and dynamics of the immune response to the BNT162b2 mRNA COVID-19 vaccine in adolescents with juvenile-onset autoimmune inflammatory rheumatic…Abstract Number: 2273 • ACR Convergence 2022
Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study
Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…Abstract Number: 0215 • ACR Convergence 2022
Online Teaching of Hand Examination Using Student-recorded Videos and Remotely Delivered Feedback: A Pilot Study
Background/Purpose: Enhancing physical examination skills improves the identification of clinical findings, decision-making and overall management. Feedback is a crucial factor in achieving effective learning but…Abstract Number: 0703 • ACR Convergence 2022
Vaccination Against SARS-CoV2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry
Background/Purpose: Some concerns have been raised with the use of vaccines against SARS-CoV-2 in patients with Systemic Autoimmune Diseases (SAD) including the risk of serious…Abstract Number: 0773 • ACR Convergence 2022
Additional Dose of SARS-CoV-2 Vaccine Improves Cross-Variant Neutralization Titers in Immunosuppressed Patients with Chronic Inflammatory Disease
Background/Purpose: Most immunosuppressed patients with chronic inflammatory diseases (CID) mount total anti-Spike (S) IgG responses following vaccination with mRNA-based SARS-CoV-2 vaccines. Less is known, however,…Abstract Number: 0794 • ACR Convergence 2022
Impact of Vaccination on Post-acute Sequelae of SARS CoV-2 Infection in Patients with Rheumatic Diseases
Background/Purpose: Post-acute sequelae of COVID-19 (PASC) refers to persistent symptoms after the resolution of acute infection and is estimated to affect over 20% of COVID-19…Abstract Number: 0991 • ACR Convergence 2022
Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
Background/Purpose: To compare use of autoimmune disease treatments between patients with and without severe COVID-19 (COVID) in cohorts of patients with systemic lupus erythematosus (SLE),…Abstract Number: 1339 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
Background/Purpose: The COVID-19 Pandemic created challenges for patients with rheumatoid arthritis (RA), including accessing the health care system, transition to unplanned virtual care, reduction in…Abstract Number: 1776 • ACR Convergence 2022
COVID-19 Cases in Patients Treated with Secukinumab: Analysis from the Global Safety Database
Background/Purpose: Although patients (pts) with immune-mediated inflammatory diseases who are taking immunosuppressive therapies are not at a significantly greater risk of SARS-CoV-2 (severe acute respiratory…Abstract Number: 1949 • ACR Convergence 2022
Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases
Background/Purpose: Effectiveness of the BNT162b2 mRNA COVID-19 vaccine for adolescents with juvenile-onset inflammatory rheumatic diseases (IRD) is unknown. Several studies suggested attenuated immunogenicity in patients…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 38
- Next Page »